Organovo Holdings Inc (NYSEMKT:ONVO) released information to update investors on the results of its initial study of 3D breast tissues generated with its NovoGen MMX Bioprinter in breast cancer models. Organovo Holdings Inc (NYSEMKT:ONVO) shares after opening at $6.67 moved to $6.88 on last trade day and at the end of the day closed at $6.64. Company price to sales ratio in past twelve months was calculated as 1033.32 and price to cash ratio as 10.37. Organovo Holdings Inc (NYSEMKT:ONVO) showed a negative weekly performance of -17.00%.
XOMA Corp (NASDAQ:XOMA) saw a significant increase in short interest during the month of January. As of March 31st, there was short interest totalling 9,384,397 shares, an increase of 43.2% from the March 14th total of 6,552,758 shares, AmericanBankingNews.com reports. Currently, 8.9% of the shares of the stock are sold short. Based on an average trading volume of 2,826,164 shares, the days-to-cover ratio is presently 3.3 days. XOMA Corp (NASDAQ:XOMA) shares advanced 6.06% in last trading session and ended the day on $4.20. XOMA its return on assets is -152.10%. XOMA Corp (NASDAQ:XOMA) yearly performance is 18.64%.
Vanda Pharmaceuticals Inc. (Vanda) (NASDAQ: VNDA) announced the availability of HETLIOZ(TM). HETLIOZ(TM) is the first treatment approved by the U.S Food and Drug Administration (FDA) for Non-24-Hour Sleep-Wake Disorder (Non-24), a serious chronic circadian rhythm disorder that affects up to 70 percent of people who are totally blind. Vanda Pharmaceuticals Inc. (NASDAQ:VNDA) shares moved up 5.05% in last trading session and was closed at $13.31, while trading in range of $12.09-$13.54. Vanda Pharmaceuticals Inc. (NASDAQ:VNDA) year to date performance is 7.25%.
BG Medicine, Inc. (Nasdaq:BGMD), the developer of the BGM Galectin-3® Test, announced that it intends to offer and sell shares of its common stock in an underwritten public offering. BG Medicine also expects to grant the underwriters a 30-day option to purchase additional shares of common stock to cover over-allotments, if any. Lazard Capital Markets LLC is acting as sole book-running manager for the offering. While the offering is expected to price before 9:30 am EDT on April 3, 2014, the offering is subject to market conditions, and there can be no assurance as to whether or when the offering may be completed, or as to the actual size or terms of the offering.BG Medicine, Inc. (NASDAQ:BGMD) weekly performance is -6.25%. On last trading day company shares ended up $1.35. BG Medicine, Inc. (NASDAQ:BGMD) distance from 50-day simple moving average is -6.20%. Analysts mean target price for the company is $2.40.
Leave a Reply